Otsuka Holdings Co. agreed to buy California-based Avanir Pharmaceuticals Inc. for about $3.54 billion, a deal that gives the Japanese company new treatments for neurological conditions.

Tokyo-based Otsuka will pay $17 a share, it said in a stock exchange statement today. That’s 13 percent higher than Avanir’s closing price of $15 yesterday.

Subscribe Now

Complete access to real-time information and analysis of news and trends in the industry.

14-Day Free Trial

No credit card required. Complete access to articles, breaking news and industry data.